Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease:: results of a randomised controlled trial

被引:153
作者
Kuipers, EJ
Nelis, GF
Klinkenberg-Knol, EC
Snel, P
Goldfain, D
Kolkman, JJ
Festen, HPM
Dent, J
Zeitoun, P
Havu, N
Lamm, M
Walan, A
机构
[1] Erasmus MC Univ Med Ctr, Dept Gastroenterol & Hepatol, NL-3000 CA Rotterdam, Netherlands
[2] Sophia Hosp, Dept Gastroenterol, Zwolle, Netherlands
[3] Free Univ Amsterdam Hosp, Dept Gastroenterol, Amsterdam, Netherlands
[4] Slotervaart Hosp, Dept Gastroenterol, Amsterdam, Netherlands
[5] Hop Victor Jusselin, Dept Gastroenterol, Dreux, France
[6] Med Spectrum Twente, Dept Gastroenterol, Enschede, Netherlands
[7] Groote Ziekengasthuis, Dept Gastroenterol, Den Bosch, Netherlands
[8] Royal Adelaide Hosp, Dept Gastroenterol, Adelaide, SA 5000, Australia
[9] Hop Robert Debre, Dept Gastroenterol, Reims, France
[10] AstraZeneca R&D, Sodertalje, Sweden
[11] AstraZeneca R&D, Molndal, Sweden
关键词
D O I
10.1136/gut.53.1.12
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Helicobacter pylori gastritis may progress to glandular atrophy and intestinal metaplasia, conditions that predispose to gastric cancer. Profound suppression of gastric acid is associated with increased severity of H pylori gastritis. This prospective randomised study aimed to investigate whether H pylori eradication can influence gastritis and its sequelae during long term omeprazole therapy for gastrooesophageal reflux disease ( GORD). Methods: A total of 231 H pylori positive GORD patients who had been treated for greater than or equal to 12 months with omeprazole maintenance therapy ( OM) were randomised to either continuation of OM ( OM only; n = 120) or OM plus a one week course of omeprazole, amoxycillin, and clarithromycin ( OM triple; n = 111). Endoscopy with standardised biopsy sampling as well as symptom evaluation were performed at baseline and after one and two years. Gastritis was assessed according to the Sydney classification system for activity, inflammation, atrophy, intestinal metaplasia, and H pylori density. Results: Corpus gastritis activity at entry was moderate or severe in 50% and 55% of the OM only and OM triple groups, respectively. In the OM triple group, H pylori was eradicated in 90 ( 88%) patients, and activity and inflammation decreased substantially in both the antrum and corpus ( p < 0.001, baseline v two years). Atrophic gastritis also improved in the corpus ( p < 0.001) but not in the antrum. In the 83 OM only patients with continuing infection, there was no change in antral and corpus gastritis activity or atrophy, but inflammation increased ( p < 0.01). H pylori eradication did not alter the dose of omeprazole required, or reflux symptoms. Conclusions: Most H pylori positive GORD patients have a corpus predominant pangastritis during omeprazole maintenance therapy. Eradication of H pylori eliminates gastric mucosal inflammation and induces regression of corpus glandular atrophy. H pylori eradication did not worsen reflux disease or lead to a need for increased omeprazole maintenance dose. We therefore recommend eradication of H pylori in GORD patients receiving long term acid suppression.
引用
收藏
页码:12 / 20
页数:9
相关论文
共 54 条
  • [1] Annibale B, 2000, ALIMENT PHARM THERAP, V14, P625
  • [2] Armitage P, 1990, STAT METHODS MED RES
  • [3] Helicobacter pylori gastritis and epithelial cell proliferation in patients with reflux oesophagitis after treatment with lansoprazole
    Berstad, AE
    Hatlebakk, JG
    Maartmann-Moe, H
    Berstad, A
    Brandtzaeg, P
    [J]. GUT, 1997, 41 (06) : 740 - 747
  • [4] Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia:: the Canadian adult dyspepsia empiric treatment -: Helicobacter pylori positive (CADET-Hp) randomised controlled trial
    Chiba, N
    van Zanten, SJOV
    Sinclair, P
    Ferguson, RA
    Escobedo, S
    Grace, E
    [J]. BRITISH MEDICAL JOURNAL, 2002, 324 (7344): : 1012 - +
  • [5] CORREA P, 1992, CANCER RES, V52, P6735
  • [6] Classification and grading of gastritis - The updated Sydney System
    Dixon, MF
    Genta, RM
    Yardley, JH
    Correa, P
    Batts, KP
    Dahms, BB
    Filipe, MI
    Haggitt, RC
    Haot, J
    Hui, PK
    Lechago, J
    Lewin, K
    Offerhaus, JA
    Price, AB
    Riddell, RH
    Sipponen, P
    Solcia, E
    Watanabe, H
    [J]. AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1996, 20 (10) : 1161 - 1181
  • [7] Prospects for intervention in gastric carcinogenesis: reversibility of gastric atrophy and intestinal metaplasia
    Dixon, MF
    [J]. GUT, 2001, 49 (01) : 2 - 4
  • [8] PREVALENCE OF HELICOBACTER-PYLORI INFECTION AND HISTOLOGIC GASTRITIS IN ASYMPTOMATIC PERSONS
    DOOLEY, CP
    COHEN, H
    FITZGIBBONS, PL
    BAUER, M
    APPLEMAN, MD
    PEREZPEREZ, GI
    BLASER, MJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (23) : 1562 - 1566
  • [9] Gastric mucosa during treatment with lansoprazole: Helicobacter pylori is a risk factor for argyrophil cell hyperplasia
    Eissele, R
    Brunner, G
    Simon, B
    Solcia, E
    Arnold, R
    [J]. GASTROENTEROLOGY, 1997, 112 (03) : 707 - 717
  • [10] Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection
    Ekström, AM
    Held, M
    Hansson, L
    Engstrand, L
    Nyrén, O
    [J]. GASTROENTEROLOGY, 2001, 121 (04) : 784 - 791